Refractory Palmoplantar Pustulosis Successfully Treated with JAK Inhibitor Tofacitinib: A Case Series
Open Access
- 1 August 2023
- journal article
- research article
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 16, 5165-5172
Abstract
Background: Palmoplantar pustulosis (PPP) is a common chronic and recurrent skin disease of the palms and soles with significant pain, mental distress, and functional disability. PPP is challenging to treat and usually requires prolonged management. Therapy resistance and frequent relapse discourages patients from follow-up. No unified standard and no published therapeutic guidelines have yet been defined on PPP treatment. In general, all therapeutic options known for autoimmune diseases, psoriasis in particular, have been tested in PPP. Tofacitinib, an oral JAK inhibitor, has been approved for the treatment of rheumatoid arthritis and shows promise in the treatment of moderate-to-severe plaque psoriasis. However, no clinical trials or case reports have been conducted to confirm the efficacy of tofacitinib in palmoplantar pustulosis. Methods: Six in total with 6 PPP patient, aged 42– 58 years were recruited according to the inclusion and exclusion criteria. Patient characteristics, including triggering factors, concomitant diseases, and previous therapeutic drugs, were investigated. All patients experienced a lack of response to topical drugs and at least one systemic agent. During treatment, visits were scheduled at the start of treatment and at 2, 4, and 12 weeks, and efficacy was assessed using the PPP ASI and PPP PGA. Results: Our six patients showed an excellent response to tofacitinib as all patients did achieve at least 50% reduction and half of our patients with more than 80% reduction in PPPASI after 4 weeks treatment; at week 12, 5 (83.3%) patients had 80% reduction in PPPASI with no serious adverse events were reported. Conclusion: The JAK inhibitor tofacitinib is a promising treatment for refractory palmoplantar pustulosis that requires further clinical observation and research.Keywords
This publication has 29 references indexed in Scilit:
- Is palmoplantar pustulosis simply a variant of psoriasis or a distinct entity?Journal of the European Academy of Dermatology and Venereology, 2017
- Psoriasis and palmoplantar pustulosis: an endless debate?Journal of the European Academy of Dermatology and Venereology, 2017
- Retrospective analysis of the clinical response of palmoplantar pustulosis after dental infection control and dental metal removalThe Journal of Dermatology, 2017
- The JAK-STAT Pathway: Impact on Human Disease and Therapeutic InterventionAnnual Review of Medicine, 2015
- Increased expression of IL‐17A and limited involvement of IL‐23 in patients with palmo‐plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trialJournal of the European Academy of Dermatology and Venereology, 2013
- Management of palmoplantar pustulosis: do we need to change?British Journal of Dermatology, 2011
- Can we really separate palmoplantar pustulosis from psoriasis?Journal of the European Academy of Dermatology and Venereology, 2010
- IL-8 as Antibody Therapeutic Target in Inflammatory Diseases: Reduction of Clinical Activity in Palmoplantar PustulosisThe Journal of Immunology, 2008
- Expression of cutaneous lymphocyte-associated antigen (CLA) in tonsillar T-cells and its induction by in vitro stimulation with alpha-streptococci in patients with pustulosis palmaris et plantaris (PPP)Clinical Immunology, 2005
- Targeting the Jak/STAT pathway for immunosuppressionAnnals of the Rheumatic Diseases, 2004